Korean Circ J.  2007 Jul;37(7):287-297. 10.4070/kcj.2007.37.7.287.

Pulmonary Arterial Hypertension of Congenital Heart Diseases: From Reversible Pulmonary Hypertension to Eisenmenger Syndrome

• Jung JW

• KMID: 2227055
• DOI: http://doi.org/10.4070/kcj.2007.37.7.287

Abstract

Congenital heart disease represents a condition commonly associated with pulmonary arterial hypertension (PAH). Eisenmenger syndrome is on the extreme end of the spectrum of PAH in the setting of congenital heart disease. This status implied the irreversibility and inoperability of a subgroup of patients with congenital heart defects. Untreated or even treated, Eisenmenger syndrome is characterized by a progressive increase in pulmonary vascular resistance that leads to right ventricular failure and death. Today, although there have been many advances in understanding of the pathophysiology of Eisenmenger syndrome and also advances in treating this disease, there is still no cure for this progressive condition, but the new vasodilators may be well tolerated and they improve the exercise capacity and hemodynamics without compromising the peripheral oxygen saturation. Eisenmenger syndrome can be prevented in most pediatric patients. With the advances in imaging, surgery and intensive care facilities and also in the early definitive therapy for the majority of lesions associated with a risk of developing Eisenmenger syndrome, a progressive decrease in the prevalence of this disease may be expected. Identifying the risk factors is problematic as the annual mortality rates are relatively low for Eisenmenger patients. We review here the available data on the pathophysiology, clinical presentation, prognosis and management of pulmonary arterial hypertension in patients with congenital heart disease.

Keyword

Congenital heart defects; Hypertension, pulmonary; Eisenmenger syndrome

MeSH Terms

Eisenmenger Complex*
Heart Defects, Congenital
Heart Diseases*
Heart*
Hemodynamics
Humans
Hypertension*
Hypertension, Pulmonary*
Critical Care
Mortality
Oxygen
Prevalence
Prognosis
Risk Factors
Vascular Resistance
Vasodilator Agents
Oxygen
Vasodilator Agents

Figure

• 

  Fig. 1 Therapeutic approaches to pulmonary hypertension. A model of the pulmonary arteriolar system and alveolus is illustrated, with the sites of action of each of the six major classes of agents.5)

• 

  Fig. 2 Algorithm for the treatment of pulmonary hypertension.19)

Reference

1. Wood P. The Eisenmenger syndrome or pulmonary hypertension with reversed central shunt. BMJ. 1958. 2:755–762.

2. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004. 126(1):Suppl. 14S–34S.

3. Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation. 2007. 115:1039–1050.

4. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004. 43:Suppl S. 40S–47S.

5. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004. 351:1655–1665.

6. Barst RJ. Recent advances in the treatment of pediatric pulmonary artery hypertension. Pediatr Clin North Am. 1999. 46:331–345.

7. Berman EB, Barst RJ. Eisenmenger's syndrome: current management. Prog Cardiovasc Dis. 2002. 45:129–138.

8. Kaemmerer H, Fratz S, Bauer U, et al. Emergency hospital admissions and three-year survival of adults with and without cardiovascular surgery for congenital cardiac disease. J Thorac Cardiovasc Surg. 2003. 126:1048–1052.

9. Keck BM, Bennett LE, Rosendale J, Daily OP, Novick RJ, Hosenpud JD. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation. Clin Transpl. 1999. 35–49.

10. Hopkins WE, Ochoa LL, Richardson GW, Trulock EP. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996. 15:100–105.

11. Hong SK, Han KR, Kim HS, et al. Eisenmenger syndrome in adult. Korean Circ J. 1992. 22:563–572.

12. Kim KH, Park JC, Lee S, et al. Clinical features and long-term clinical outcomes of adult atrial septal defects. Korean Circ J. 2006. 36:695–700.

13. Steele PM, Fuster V, Cohen M, Ritter DG, McGoon DC. Isolated atrial septal defect with pulmonary vascular obstructive disease: long-term follow-up and prediction of outcome after surgical correction. Circulation. 1987. 76:1037–1042.

14. Silversides CK, Granton JT, Konen E, Hart MA, Webb GD, Therrien J. Pulmonary thrombosis in adults with Eisenmenger syndrome. J Am Coll Cardiol. 2003. 42:1982–1987.

15. Daliento L, Somerville J, Presbitero P, et al. Eisenmenger syndrome: factors relating to deterioration and death. Eur Heart J. 1998. 19:1845–1855.

16. Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J. 2004. 25:2243–2278.

17. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005. 143:282–292.

18. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation. 1958. 18:533–547.

19. Ito T, Ozawa K, Shimada K. Current drug targets and future therapy of pulmonary arterial hypertension. Curr Med Chem. 2007. 14:719–733.

20. Benisty JL, Landzberg MJ. Eisenmenger's syndrome. Curr Trea Options Cardiovasc Med. 1999. 1:355–362.

21. Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med. 1988. 109:406–413.

22. Kim HY. A case of Eisenmenger syndrome with brain abscess. Korean Circ J. 1999. 29:79–83.

23. Chung SM, Kim SH, Ryu KH, Kim HJ, Han SW, Lee Y. Impact of pulmonary hypertension on the regional right ventricular strain. Korean Circ J. 2006. 36:578–582.

24. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004. 126:35S–62S.

25. Therrien J, Warnes C, Daliento L, et al. Canadian Cardiovascular Society Consensus Conference 2001 update: recommendations for the management of adults with congenital heart disease part III. Can J Cardiol. 2001. 17:1135–1158.

26. Diller GP, Dimopoulos K, Broberg CS, et al. Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. Eur Heart J. 2006. 27:1737–1742.

27. Warnes CA. Pregnancy and pulmonary hypertension. Int J Cardiol. 2004. 97:11–13.

28. Sreeram N. Eisenmenger syndrome: towards identifying the risk factors for death. Eur Heart J. 2006. 27:1644–1645.

29. Broberg CS, Uebing A, Cuomo L, Thein SL, Papdopoulous MG, Gatzoulis MA. Adult patients with Eisenmenger syndrome report flying safely on commercial airlines. Heart. 2007. 93:1599–1603. Available from: URL: http://heart.bmj.com/cgi/content/abstract/93/12/1599.

30. Waddell TK, Bennett L, Kennedy R, Todd TR, Keshavjee SH. Heart-lung or lung transplantation for Eisenmenger syndrome. J Heart Lung Transplant. 2002. 21:731–737.

31. Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation. 2005. 111:3274–3280.

32. Galie N, Beghetti M, Gatzoulis MA, et al. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation. 2006. 114:48–54.

33. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004. 126(1):Suppl. 78S–92S.

34. Cantor WJ, Harrison DA, Moussadji JS, et al. Determinants of survival and length of survival in adults with Eisenmenger syndrome. Am J Cardiol. 1999. 84:677–681.